Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naive patients with compensated cirrhosis: real-world experience from Taiwan HCV registry Chao-Hung Hung , Te-Sheng Chang , Chung-Feng Huang , Hsing-Tao Kuo , Ching-Chu Lo , Chien-Wei Huang , Lee-Won Chong , Pin-Nan Cheng , Ming-Lun Yeh , Cheng-Yuan Peng , Chien-Yu Cheng , Jee-Fu Huang , Ming-Jong Bair , Chih-Lang Lin , Chi-Chieh Yang , Sih-Ren Wang , Tsai-Yuan Hsieh , Tzong-Hsi Lee , Pei-Lun Lee , Wen-Chih Wu , Chih-Lin Lin , Wei-Wen Su , Shengshun Yang , Chia-Chi Wang , Jui-Ting Hu , Lien-Juei Mou , Chun-Ting Chen , Yi-Hsiang Huang , Chun-Chao Chang , Jia-Sheng Huang , Guei-Ying Chen , Jian-Neng Gao , Chi-Ming Tai , Chun-Jen Liu , Mei-Hsuan Lee , Pei-Chien Tsai , Chia-Yen Dai , Jia-Horng Kao , Han-Chieh Lin , Wan-Long Chuang , Chiyi Chen , Kuo-Chih Tseng , Ming-Lung Yu JOURNAL OF HEPATOLOGY（2022）
关键词
hcv treatment naïve patients, glecaprevir/pibrentasvir, taiwan hcv registry, cirrhosis, real-world
AI 理解论文
溯源树
样例
